Startup profile · funding coverage
Cartography Biosciences
Oncology biotech building an antigen atlas for precise antibody immunotherapies.
Stage
series b
Status
private
Coverage
full
Why Cartography Biosciences is interesting
Maps tumor-specific antigens systematically — 8VC-led Series A with a16z seed continuity into Pfizer Ventures-led Series B.
Key facts
- Series B (2025): $67M led by Pfizer Ventures; 8VC, Gaingels, a16z among existing investors (BusinessWire)
- Series A (2022): $57M led by 8VC; a16z (seed lead) and Wing participated (a16z announcement)
Investors in our directory
Funds linked from Cartography Biosciences's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about Cartography Biosciences
Funding context and why this company shows up in venture coverage.
Cartography systematically identifies antigens present on tumors but not healthy tissue, then develops antibody therapies against those targets for cancer treatment.
Andreessen Horowitz (see /fund/andreessen-horowitz) led the seed. 8VC (see /fund/8vc) led the $57M Series A; Pfizer Ventures led the $67M Series B in 2025 with a16z and 8VC re-upping.
Series B ($67M, 2025). The South San Francisco biotech remains private.
Precision oncology needs better target selection — Cartography's antigen atlas approach reduces off-tumor toxicity risk in antibody immunotherapy development.
No — Cartography Biosciences remains a private biotech.
Last updated: 2026-07-24